scholarly journals ABO Blood Group Incompatibility Protects Against SARS-CoV-2 Transmission

2022 ◽  
Vol 12 ◽  
Author(s):  
Rachida Boukhari ◽  
Adrien Breiman ◽  
Jennifer Jazat ◽  
Nathalie Ruvoën-Clouet ◽  
Salima Martinez ◽  
...  
Keyword(s):  
Blood Group ◽  
Hospital Staff ◽  
Blood Type ◽  
Abo Blood Group ◽  
Staff Members ◽  
Abo Incompatibility ◽  
Real Importance ◽  
Abo Blood Type ◽  
Underlying Mechanisms ◽  
Protein Attachment

ABO blood groups appear to be associated with the risk of SARS-CoV-2 infection, but the underlying mechanisms and their real importance remain unclear. Two hypotheses have been proposed: ABO compatibility-dependence (neutralization by anti-ABO antibodies) and ABO-dependent intrinsic susceptibility (spike protein attachment to histo-blood group glycans). We tested the first hypothesis through an anonymous questionnaire addressed to hospital staff members. We estimated symptomatic secondary attack rates (SAR) for 333 index cases according to spouse ABO blood group compatibility. Incompatibility was associated with a lower SAR (28% vs. 47%; OR 0.43, 95% CI 0.27–0.69), but no ABO dependence was detected in compatible situations. For the second hypothesis, we detected no binding of recombinant SARS-CoV-2 RBD to blood group-containing glycans. Thus, although no intrinsic differences in susceptibility according to ABO blood type were detected, ABO incompatibility strongly decreased the risk of COVID-19 transmission, suggesting that anti-ABO antibodies contribute to virus neutralization.

ABO blood group and the risk of breast cancer: Multicenter, case-control, observational study.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1572-1572
Author(s):  
Yuksel Urun ◽  
Tulay Koru-Sengul ◽  
Kadri Altundag ◽  
Gungor Utkan ◽  
Handan Onur ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Blood Group ◽  
Blood Groups ◽  
Blood Type ◽  
Abo Blood Group ◽  
Abo Blood Groups ◽  
Blood Types ◽  
Abo Blood Type

1572 Background: The role of genetic factors in the development of cancer is widely accepted. ABO blood type is an inherited characteristic and previous studies have observed an association between ABO blood group and risk of certain malignancies, including pancreatic and gastric cancer. The data on the role of ABO blood group and Rh factor in breast cancer is inconclusive. Methods: All patients who had breast cancer (BC) and treated between 2000-2010 at the Departments of Medical Oncology of both Ankara and Hacettepe Universities (Ankara, Turkey) with defined ABO blood type and Rh factor were included in our retrospective reviews of tumor registry records. A group of volunteer healthy women donors of Turkish Red Crescent between 2004-2011 were identified as a control group, without any matching factors. The relationship of ABO blood types and Rh factor with various prognostic factors such as age at diagnosis, menopausal status, family history of breast cancer, and ER/PR/HER2 status were evaluated from 1740 BC patients. We compared the distributions of ABO blood types, Rh factors among 1740 patients and 204,553 healthy controls. Among BC patients, differences between each of aforementioned ABO blood groups and Rh factors with respect to various prognostic factors were explored, respectively. Results: Overall distributions of ABO blood groups as well as Rh factor were comparable between patients (44% A, 8% AB, 16% B, 32% O, 88% Rh+) and controls (41% A, 8% AB, 16% B, 35% O, 87% Rh+). However, there were statistically significant differences between patients and controls with respect to A vs. nonA (p=0.019) and marginal significance (p=0.051) for O vs. nonO. Among patients, there were statistically significant differences between A and nonA with respect to HER2 (p=0.0421), M stage (p=0.0447), T stage (p=0.0020). Only T stage (p=0.0337) were significantly different between O vs nonO. Grade (p=0.0227) and M stage (p=0.0107) were significantly different between Rh factors. Conclusions: In our study sample, ABO blood type was statistically significantly associated with breast cancer. Additional studies are necessary to determine the mechanisms by which ABO blood type may influence the risk of breast cancer.

ABO blood group and the risk of lung cancer: Multicenter, case-control, observational study.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1596-1596
Author(s):  
Gungor Utkan ◽  
Yuksel Urun ◽  
Ayten Kayi Cangir ◽  
Omur Berna Oksuzoglu ◽  
Nuriye Özdemir ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Blood Group ◽  
Clinical Features ◽  
Blood Type ◽  
Control Group ◽  
Abo Blood Group ◽  
Significant Difference ◽  
Abo Blood Type ◽  
Relationship Of

1596 Background: The role of genetic factors in the development of cancer is widely accepted. Previous studies have observed an association between ABO blood group and risk of certain malignancies, including pancreatic and gastric cancer. The data on the role of ABO blood group and Rh factor in lung cancer is limited. Methods: All patients who had Lung cancer (LC) and treated between 2000-2011 at the involved centers with defined ABO/Rh were included in our retrospective reviews of tumor registry records. A group of volunteer healthy blood donors of Turkish Red Crescent between 2004 and 2011 were identified as a control group. The relationship of ABO/Rh with clinical features such as age at diagnosis, histological subtype and sex were evaluated. We compared the distributions of ABO/Rh among 1954 patients and 3,022,883 controls. Among LC patients, differences between each of aforementioned ABO/Rh groups with respect to various clinical features were explored, respectively. Results: Of these patients the median age was 62 (range: 17-90). The 84% of patients were male. Overall distributions of ABO blood groups as well as Rh factor were statistically different between patients (43.6% A, 8.3% AB, 17.3% B, 30.8% O, and 86.3% Rh+) and controls (42.2% A, 7.6% AB, 16.3% B, 33.9% O, and 87.7% Rh+) (p=0,03). In addition, there were statistically significant differences between patients and controls with respect to O vs. nonO (p=0.004) and marginal significance for A vs. nonA (p=0,065), B vs. nonB (p=0,076), and Rh+ vs. Rh- (p=0,057). Among patients, there weren’t statistically significant differences between blood group with respect to sex and age. However there was statistically significant difference between blood group with respect to histology (p=0,001). Although the distribution of A and O were similar according to histology, patients with squamous histology had antigen B more frequently than other histological sub types (p=0,009). Conclusions: In the study populations, ABO blood type was statistically significantly associated with the LC and having blood type other than O increases the risk of LC. Further studies are necessary to define the mechanisms by which ABO blood type may influence breast cancer risk.

ABO blood group and risk of lethal prostate cancer.

2014 ◽  
Vol 32 (4_suppl) ◽  
pp. 69-69 ◽  
Author(s):  
Yuksel Urun ◽  
Kathryn M Wilson ◽  
Irene M. Shui ◽  
Edward L. Giovannucci ◽  
Brian M. Wolpin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Blood Group ◽  
Specific Antigen ◽  
Cox Proportional Hazards ◽  
Blood Type ◽  
Abo Blood Group ◽  
Increased Risk ◽  
Abo Blood Type ◽  
Lethal Prostate Cancer

69 Background: An individual’s blood group is defined by variability in glycotransferases expressed on red blood cell surface; these ABO antigens are also highly expressed on epithelial cells. Previous studies have suggested associations between ABO blood group and increased risk of epithelial cancers including gastric, pancreatic, and ovarian; however, its relationship with risk of prostate carcinoma, and its aggressiveness remains unclear. Methods: We prospectively evaluated the association between ABO blood group and risk of lethal prostate cancer in the Health Professionals Follow-up Study (HPFS) from 1996 to 2008. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional hazards models with adjustment for other risk factors and prostate-specific antigen testing. Results: During 12 years of follow-up of 26,602 men, 2,703 cases of incident prostate cancer were documented, including 289 lethal cases (prostate cancer death or distant metastases). The frequency of ABO blood type was similar between men who developed prostate cancer (37% A, 7% AB, 13% B, and 43% O) and other participants (37% A, 8% AB, 12% B, and 43% O). On multivariate analysis, blood type was not associated with overall prostate cancer incidence. However, compared to men with blood group O, those with blood group AB were significantly less likely to develop lethal prostate cancer (multivariate-adjusted HR = 0.39 [95% confidence interval {CI} = 0.18-0.85]). There was no association between type B or A compared to O with lethal disease. ABO blood type was not significantly associated with the risk of advanced stage or high-grade cancers (Gleason score 8 to 10). Conclusions: Blood group AB was associated with a lower risk of lethal prostate cancer compared to blood group O. Further studies are needed to replicate these findings and to clarify possible biological mechanisms underlying this association.

scholarly journals Modelling suggests blood group incompatibility may substantially reduce SARS-CoV-2 transmission

2020 ◽  
Author(s):  
Peter James Ellis
Keyword(s):  
Theoretical Model ◽  
Blood Group ◽  
Group Interaction ◽  
Virus Transmission ◽  
Type A ◽  
Blood Type ◽  
Published Data ◽  
Abo Blood Group ◽  
High Susceptibility ◽  
Abo Incompatibility

Several independent datasets suggest blood type A is over-represented and type O under-represented among COVID-19 patients. Here, I model a scenario in which ABO transfusion incompatibility reduces the chance of a patient transmitting the virus to an incompatible recipient. Comparison of model outputs to published data on COVID-19 prevalence indicates that if this scenario holds true, ABO incompatibility may reduce virus transmissibility by 60% or more. Paradoxically, however, targeted vaccination of either high-susceptibility type A or "super-spreader" type O individuals is less effective than random vaccination at blocking community spread of the virus. Instead, the key is to maintain blood type diversity amongst the remaining susceptible individuals. I stress that these results illustrate a theoretical model of ABO blood group interaction with virus transmission and require confirmation by observation.

scholarly journals EFFECT OF MATERNAL ABO BLOOD TYPE ON BIRTH WEIGHT

2021 ◽  
pp. 183-186
Author(s):  
Dr.Himanshu S Dave ◽  
Dr.Tanushree Joshi ◽  
Dr.Kathakali Das ◽  
Dr.Dimple Pal
Keyword(s):  
Birth Weight ◽  
Low Birth Weight ◽  
Blood Group ◽  
Pregnancy Outcomes ◽  
Adverse Pregnancy Outcomes ◽  
Blood Type ◽  
Abo Blood Group ◽  
Type B ◽  
Abo Blood Type ◽  
Adverse Pregnancy

Background: ABO blood group has been recognized as a risk factor for distinct disease states. The association between ABO blood group and adverse pregnancy outcomes has not been extensively studied, especially in relation to birth weight. The aim of the present study is to determine whether ABO blood group contributes to the adverse pregnancy outcomes like low birth weight. Methods: Medical data including ABO phenotypes were collected from hospital database and retrospectively reviewed. Adverse pregnancy outcome studied was low birth weight. Birth week was also noted for each subject. Results: 500 charts of mothers who had given birth in our hospital were studied. Overall 146 (29.2%) women had type O blood, 108 (21.6%) had type A blood, 194 (38.8%) had type B blood and 52 (10.4%) had type AB blood. Pregnant women with type B blood group had significantly lower birth weights compared with type O, A and AB. Birth weeks of all groups were found to be similar with no statistically significant difference Conclusions: Maternal ABO phenotype is associated with low birth weight, while no association was found between blood type and birth week. We postulate that maternal/fetal immune system genes which are directly associated with ABO blood groups could affect pregnant with a resulting birth weight alterations. KEYWORDS: ABO blood type, Birth weight, Pregnancy.

scholarly journals Prognostic Role of ABO Blood Type in Operable Esophageal Cancer: Analysis of 2179 Southern Chinese Patients

2020 ◽  
Vol 10 ◽  
Author(s):  
Shuishen Zhang ◽  
Minghan Jia ◽  
Xiaoli Cai ◽  
Weixiong Yang ◽  
Shufen Liao ◽  
...  
Keyword(s):  
Blood Group ◽  
Disease Free Survival ◽  
Blood Type ◽  
Chinese Patients ◽  
Abo Blood Group ◽  
Prognostic Impact ◽  
Type B ◽  
Blood Types ◽  
Southern Chinese ◽  
Abo Blood Type

BackgroundThe prognostic value of ABO blood types is not well clarified for esophageal carcinoma (EC). This study attempted to elucidate the associations between different ABO blood types and disease-free survival (DFS) and overall survival (OS) of EC.MethodsThis study was a retrospective review of the records of 2179 patients with EC who received surgery from December 2000 to December 2008. The prognostic impact of ABO blood group on DFS and OS were estimated using the Kaplan-Meier method and cox proportional hazard models.ResultsUnivariate analyses found significant differences in DFS and OS among the four blood types. Multivariate analyses showed ABO blood type independently predicted DFS (P=0.001) and OS (P=0.002). Furthermore, patients with non-B blood types had a significantly shorter DFS (HR=1.22, 95%CI:1.07–1.38, P=0.002) and OS (HR=1.22, 95%CI:1.07–1.38, P=0.003) than patients with blood type B, and patients with non-O blood types had a significantly better DFS (HR=0.86, 95%CI:0.77–0.96, P=0.006) and OS (HR=0.86, 95%CI:0.77–0.96, P=0.007) than patients with blood type O. Subgroup analyses found that blood type B had a better DFS and OS than non-B in patients who were male, younger, early pathological stages and had squamous-cell carcinomas (ESCC). Blood type O had a worse DFS and OS than non-O in patients who were male, younger, and had ESCC (P<0.05).ConclusionsThe results demonstrate that ABO blood group is an independent prognostic factor of survival, and that type B predicts a favorable prognosis, whereas type O predicts an unfavorable prognosis for survival in patients with EC, especially those with ESCC.

scholarly journals Relationship between the ABO Blood Group and the COVID-19 Susceptibility

2020 ◽  
Author(s):  
Jiao Zhao ◽  
Yan Yang ◽  
Hanping Huang ◽  
Dong Li ◽  
Dongfeng Gu ◽  
...  
Keyword(s):  
Blood Group ◽  
Blood Groups ◽  
Blood Type ◽  
Abo Blood Group ◽  
The Novel ◽  
Group A ◽  
Abo Blood Type ◽  
Novel Coronavirus ◽  
The Relationship ◽  
Group Distribution

AbstractThe novel coronavirus disease-2019 (COVID-19) has been spreading around the world rapidly and declared as a pandemic by WHO. Here, we compared the ABO blood group distribution in 2,173 patients with COVID-19 confirmed by SARS-CoV-2 test from three hospitals in Wuhan and Shenzhen, China with that in normal people from the corresponding regions. The results showed that blood group A was associated with a higher risk for acquiring COVID-19 compared with non-A blood groups, whereas blood group O was associated with a lower risk for the infection compared with non-O blood groups. This is the first observation of an association between the ABO blood type and COVID-19. It should be emphasized, however, that this is an early study with limitations. It would be premature to use this study to guide clinical practice at this time, but it should encourage further investigation of the relationship between the ABO blood group and the COVID-19 susceptibility.

A Caution in Association of ABO Blood Group with COVID-19

2020 ◽  
Keyword(s):  
Gene Cluster ◽  
Clinical Outcomes ◽  
Blood Group ◽  
Association Analysis ◽  
Blood Type ◽  
Genome Wide Association ◽  
Chromosome 3 ◽  
Abo Blood Group ◽  
Genome Wide Association Analysis ◽  
Genome Wide

A comment on Zhao J, Yang Y, Huang H, Li D, Gu D, Lu X, et al. Association of ABO blood group and Covid19 susceptability. medRxiv [PREPRINT]. 2020; https://doi.org/10.1101/2020.03.11.20031096. Zeng X, Fan H, Lu D, Huang F, Meng X, Li Z, et al. Association between ABO blood group and clinical outcomes of Covid19. medRxiv[PREPRINT].2020; https://doi.org/10.1101/2020.04.15.20063107. Zietz M, Tatonetti N. Testing the association between blood type and COVID-19 infection, intubation, and death medRxiv [PREPRINT]. 2020; https://doi.org/10.1101/2020.04.08.20058073. Ellinghaus D, Degenhardt F, Bujanda L, al. e. The ABO blood group and a chromosome 3 gene cluster associate with SRAS-CoV2 respitarory failure in an Italy-Spain genome-wide association analysis. medRxiv. 2020; https://doi.org/10.1101/2020.05.31.20114991.

scholarly journals Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients

Blood ◽  
2019 ◽  
Vol 134 (11) ◽  
pp. 880-891 ◽  
Author(s):  
Laura L. Swystun ◽  
Kenichi Ogiwara ◽  
Orla Rawley ◽  
Christine Brown ◽  
Ilinca Georgescu ◽  
...  
Keyword(s):  
Blood Group ◽  
Von Willebrand Factor ◽  
Half Life ◽  
Hemophilia A ◽  
Blood Type ◽  
Abo Blood Group ◽  
Genetic Determinants ◽  
Group Status ◽  
Von Willebrand ◽  
Willebrand Factor

Abstract Factor VIII (FVIII) pharmacokinetic (PK) properties show high interpatient variability in hemophilia A patients. Although previous studies have determined that age, body mass index, von Willebrand factor antigen (VWF:Ag) levels, and ABO blood group status can influence FVIII PK, they do not account for all observed variability. In this study, we aim to describe the genetic determinants that modify the FVIII PK profile in a population of 43 pediatric hemophilia A patients. We observed that VWF:Ag and VWF propeptide (VWFpp)/VWF:Ag, but not VWFpp, were associated with FVIII half-life. VWFpp/VWF:Ag negatively correlated with FVIII half-life in patients with non-O blood type, but no correlation was observed for type O patients, suggesting that von Willebrand factor (VWF) half-life, as modified by the ABO blood group, is a strong regulator of FVIII PK. The FVIII-binding activity of VWF positively correlated with FVIII half-life, and the rare or low-frequency nonsynonymous VWF variants p.(Arg826Lys) and p.(Arg852Glu) were identified in patients with reduced VWF:FVIIIB but not VWF:Ag. Common variants at the VWF, CLEC4M, and STAB2 loci, which have been previously associated with plasma levels of VWF and FVIII, were associated with the FVIII PK profile. Together, these studies characterize the mechanistic basis by which VWF clearance and ABO glycosylation modify FVIII PK in a pediatric population. Moreover, this study is the first to identify non-VWF and non-ABO variants that modify FVIII PK in pediatric hemophilia A patients.

Influence of ABO blood group on the natural history of advanced pancreatic adenocarcinoma (PC).

2013 ◽  
Vol 31 (4_suppl) ◽  
pp. 307-307
Author(s):  
MinYuen Teo ◽  
Mohd Syahizul Nuhairy Mohd Sharial ◽  
Jarushka Naidoo ◽  
Anuradha Jayaram ◽  
Thevaraajan Jayaraman ◽  
...  
Keyword(s):  
Blood Group ◽  
Peritoneal Dissemination ◽  
Type A ◽  
Blood Type ◽  
Inclusion Criteria ◽  
Entire Cohort ◽  
History Of ◽  
Abo Blood Type ◽  
Advanced Pancreatic Adenocarcinoma ◽  
Pro Inflammatory Cytokines

307 Background: An association between blood group (ABO) and PC has been demonstrated at epidemiologic and genomic levels. Variations in ABO type may lead to higher pro-inflammatory cytokines levels with modifications in cellular adhesionand signalling promoting carcinogenesis. This study investigated the influence of ABO on the clinical behaviour of advanced PC in patients (pts) , treated with chemotherapy (ctx). Methods: Pts with confirmed PC were identified from 4 institutional databases. Inclusion criteria were unresectable (UPC) or metastatic disease (MPC), receipt of ctx and availability of ABO data. Clinicopathologic details were collected. 200 random anonymied non-cancer ABO samples were collected as control. Descriptive statistics and survival analyses were performed. Results: Between 2001 and 2012, 222 pts met inclusion criteria. Median age was 63 years (range: 33 – 83) 56% were males. 60% of pts had MPC and 27% received doublet ctx. ABO distribution was: A (40%), AB (5%), B (11%) and O (44%). The incidence of blood type A was higher in PC cohort than control (40 vs 30%, p=.03) but identical between UPC and MPC (41 vs 40%, p=.84). Overall survival between type A and non A were identical for the entire cohort (5.8 vs 6.6 mos, HR 1.04 95% CI 0.76 – 1.40, p=.82), UPC (7.6 vs 9.5 mos, HR 1.08 95% CI 0.65 – 1.76, p=.77) or MPC (5.4 vs 4.7 mos, HR 0.94 95% CI 0.66 – 1.34, p=.78). For UPC, 56 pts (64%) had radiographic documentation of the pattern of progression. Type A pts had lower propensity for developing distant metastasis (7/21) than non A (23/35), at 33 vs 66%, p=0.03. Amongst pts with MPC, the incidence of hepatic and pulmonary metastases for type A and non A were identical (77 vs 74%, p=.83; 21 vs 18%, p=.81). However, peritoneal dissemination was less common in type A pts (6 vs 23%, p=.01). Conclusions: Consistent with existing epidemiologic data, the incidence of blood type A is significantly higher in pts with PC, although this does not appear to be stage dependent. ABO did not appear to influence OS in this cohort. However, our data suggests that the pattern of disease spreadmay be related to the ABO blood type. ABO-related glycosylated products could be a target for disease modulation in further studies.

Sign in / Sign up

Export Citation Format

Share Document